Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606273 | 0.89 | MAPT (0.45) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL23875735 | 0.87 | MAPT (0.44) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL30477867 | 0.83 | MAPT (0.52) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL10019438 | 0.83 | MAPT (0.52) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL13580077 | 0.83 | MAPT (0.52) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL12388896 | 0.83 | MAPT (0.52) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL9006076 | 0.82 | MAPK14 (0.44) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL606274 | 0.82 | MAPT (0.40) | RAPGEF4MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL1655412 | 0.81 | CNR2 (0.46) | — | |
| SCHEMBL3718540 | 0.80 | HPGD (0.59) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110186834-A1 | NOVEL 1,3,5-TRIS(DIARYLAMINO)BENZENE AND USE THEREOF | BANDO CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2341043-A1 | NOVEL 1,3,5-TRIS(DIARYLAMINO)BENZENE AND USE THEREOF | Bando Chemical Industries, Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110186834-A1 | NOVEL 1,3,5-TRIS(DIARYLAMINO)BENZENE AND USE THEREOF | CBR1, CYP1B1, CBR3 | RAPGEF4 4195/4885MAPT 4623/4885RAB9A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.